RECOMBINATE 1000 IU

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

COAGULATION FACTOR VIII RECOMBINANT 1000 IU/VIAL

Disponibbli minn:

TEVA MEDICAL MARKETING LTD.

Kodiċi ATC:

B02BD02

Għamla farmaċewtika:

POWDER FOR SOLUTION FOR INJECTION

Rotta amministrattiva:

I.V

Manifatturat minn:

BAXTER S.A., BELGIUM

Grupp terapewtiku:

COAGULATION FACTOR VIII

Indikazzjonijiet terapewtiċi:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Data ta 'l-awtorizzazzjoni:

2010-07-01